PACE Team’s Work for Insurance Companies Is “Not Related” to PACE. Really? (Reprise)

By David Tuller, DrPH

When I first investigated the PACE trail in 2015, one of the features most shocking to me was the investigators’ blatant violation of a core human rights document that they had promised in their protocol to adhere to. That violation of the Declaration of Helsinki involved their failure to tell study participants about their close ties with the insurance industry. For years, the lead investigators had advised disability insurers that the interventions being tested in PACE for efficacy were in fact effective and could get claimants back to work.

For reasons that I don’t quite understand, this breach of the Declaration of Helsinki has received relatively little attention in the PACE debate–perhaps because PACE has so many disastrous methodological problems that “mere” ethical ones have taken a back seat. However, Professor MIchael Sharpe has recently performed an act of public service–through his decision to blame Guardian columnist George Monbiot for causing Long COVID, he has redirected attention back to the PACE trial. So I thought it would be useful to repost my first piece about these insurance industry ties.

This topic is also relevant now, since Berkeley is once again crowdfunding to support my project. Professor Sharpe in particular has whined about this, charging that I am being paid to trash his work. As I have explained, I worked on this project for 2-3 years with no support, so that proves I was happy to trash his work for free. At this point, my project is about investigating problematic research in this field, and that’s what I’m doing. My crowdfunding is public and sponsored by Berkeley. Everyone knows about it–unlike the naive PACE participants, who were not informed of Professor Sharpe’s cozy relationship with UNUMProvident, for example.

Below is an edited version of the piece that ran on November 17, 2015.


In my initial story on Virology Blog, I charged the PACE investigators with violating the Declaration of Helsinki, developed in the 1950s by the World Medical Association to protect human research subjects. The declaration mandates that scientists disclose “institutional affiliations” and “any possible conflicts of interest” to prospective trial participants as part of the process of obtaining informed consent.

The investigators promised in their protocol to adhere to this foundational human rights document, among other ethical codes. Despite this promise, they did not tell prospective participants about their financial and consulting links with insurance companies, including those in the disability sector. That ethical breach raises serious concerns about whether the “informed consent” they obtained from all 641 of their trial participants was truly “informed,” and therefore legitimate.

The PACE investigators do not agree that the lack of disclosure is an ethical breach. In their response to my Virology Blog story, they did not even mention the Declaration of Helsinki or explain why they violated it in seeking informed consent. Instead, they defended their actions by noting that they had disclosed their financial and consulting links in the published articles, and had informed participants about who funded the research–responses that did not address the central concern.

“I find their statement that they disclosed to The Lancet but not to potential subjects bemusing,” said Jon Merz, a professor of medical ethics at the University of Pennsylvania. “The issue is coming clean to all who would rely on their objectivity and fairness in conducting their science. Disclosure is the least we require of scientists, as it puts those who should be able to trust them on notice that they may be serving two masters.”

In their Virology Blog response, the PACE team also stated that no insurance companies were involved in the research, that only three of the 19 investigators “have done consultancy work at various times for insurance companies,” and that this work “was not related to the research.” The first statement was true, but direct involvement in a study is of course only one possible form of conflict of interest. The second statement was false. According to the PACE team’s conflict of interest disclosures in The Lancet, the actual number of researchers with insurance industry ties was four—along with the three principal investigators, physiotherapist Jessica Bavington acknowledged such links.

But here, I’ll focus on the third claim–that their consulting work “was not related to the research.” In particular, I’ll examine an online article posted by Swiss Re, a large reinsurance company. The article describes a “web-based discussion group” held with Peter White, the lead PACE investigator, and reveals some of the claims-assessing recommendations arising from that presentation. White included consulting work with Swiss Re in his Lancet disclosure.

The Lancet published the PACE results in February, 2011; the undated Swiss Re article was published sometime within the following year or so. The headline: “Managing claims for chronic fatigue the active way.” (Note that this headline uses “chronic fatigue” rather than “chronic fatigue syndrome,” although chronic fatigue is a symptom common to many illnesses and is quite distinct from the disease known as chronic fatigue syndrome. Understanding the difference between the two would likely be helpful in making decisions about insurance claims.)

The Swiss Re article noted that the illness “can be an emotive subject” and then focused on the implications of the PACE study for assessing insurance claims. It started with a summary account of the findings from the study, reporting that the “active rehabilitation” arms of cognitive behavioral therapy and graded exercise therapy “resulted in greater reduction of patients’ fatigue and larger improvement in physical functioning” than either adaptive pacing therapy or specialist medical care, the baseline condition. (The three intervention arms also received specialist medical care.)

The trial’s “key message,” declared the article, was that “pushing the limits in a therapeutic setting using well described treatment modalities is more effective in alleviating fatigue and dysfunction than staying within the limits imposed by the illness traditionally advocated by ‘pacing.’”

Added the article: “If a CFS patient does not gradually increase their activity, supported by an appropriate therapist, then their recovery will be slower. This seems a simple message but it is an important one as many believe that ‘pacing’ is the most beneficial treatment.”

This understanding of the PACE research—presumably based on information from Peter White’s web-based discussion—was wrong. Pacing is not and has never been a “treatment.” It is also not one of the “four most commonly used therapies,” as the newsletter article declared, since it has never been a “therapy” either. It is a self-help method practiced by many patients seeking the best way to manage their limited energy reserves.

The PACE investigators did not test pacing. Instead, the intervention they dubbed “adaptive pacing therapy” was an operationalized version of “pacing” developed specifically for the study. Many patients objected to the trial’s form of pacing as overly prescriptive, demanding and unlike the version they practiced on their own. Transforming an intuitive, self-directed approach into a “treatment” administered by a “therapist” was not a true test of whether the self-help approach is effective, they argued–with significant justification. Yet the Swiss Re article presented “adaptive pacing therapy” as if it were identical to “pacing.”

The Swiss Re article did not mention that the reported improvements from “active rehabilitation” were based on subjective outcomes and were not supported by the study’s objective data. Nor did it report any of the major flaws of the PACE study or offer any reasons to doubt the integrity of the findings.

The article next asked, “What can insurers and reinsurers do to assist the recovery and return to work of CFS claimants?” It then described the conclusions to be drawn from the discussion with White about the PACE trial—the “key takeaways for claims management.”

First, Swiss Re advised its employees, question the diagnosis, because “misdiagnosis is not uncommon.”

The second point was this: “It is likely that input will be required to change a claimant’s beliefs about his or her condition and the effectiveness of active rehabilitation…Funding for these CFS treatments is not expensive (in the UK, around £2,000) so insurers may well want to consider funding this for the right claimants.”

Translation: Patients who believe they have a medical disease are wrong, and they need to be persuaded that they are wrong and that they can get better with therapy. Insurers can avoid large payouts by covering the minimal costs of these treatments for patients vulnerable to such persuasion, given the right “input.”

Finally, the article warned that private therapists might not provide the kinds of “input” required to convince patients they were wrong. Instead of appropriately “active” approaches like cognitive behavior therapy and graded exercise therapy, these therapists might instead pursue treatments that could reinforce claimants’ misguided beliefs about being seriously ill, the article suggested.

“Check that private practitioners are delivering active rehabilitation therapies, such as those described in this article, as opposed to sick role adaptation,” the Swiss RE article advised. (The PACE investigators, drawing on the concept known as “the sick role” in medical sociology, have long expressed concern that advocacy groups enabled patients’ condition by bolstering their conviction that they suffered from a “medical disease,” as Michael Sharpe, another key PACE investigator, noted in a 2002 UNUMProvident report. This conviction encouraged patients to demand social benefits and health care resources rather than focus on improving through therapy, Sharpe wrote.)

Lastly, the Swiss Re article addressed “a final point specific to claims assessment.” A diagnosis of chronic fatigue syndrome, stated the article, provided an opportunity in some cases to apply a mental health exclusion, depending upon the wording of the policy. In contrast, a diagnosis of myalgic encephalomyelitis did not.

Presumably, after White disseminated the good news about the PACE results at the web-based discussion, Swiss Re’s claims managers felt better equipped to help ME/CFS claimants. And presumably that help included coverage for cognitive behavior therapy and graded exercise therapy so that claimants could receive the critical “input” they needed in order to recognize and accept that they didn’t have a medical disease after all.

In sum, contrary to the investigators’ argument in their response to Virology Blog, the PACE research and findings appear to be very much “related to” insurance industry consulting work. The claim that these relationships did not represent “possible conflicts of interest” and “institutional affiliations” requiring disclosure under the Declaration of Helsinki cannot be taken seriously.

Update 11/17/15 12:22 PM: I should have mentioned in the story that, in the PACE trial, participants in the cognitive behavior therapy and graded exercise therapy arms were no more likely to have increased their hours of employment than those in the other arms. In other words, there was no evidence for the claims presented in the Swiss Re article, based on Peter White’s presentation, that these treatments were any more effective in getting people back to work.

The PACE investigators published this employment data in a 2012 paper in PLoS One. It is unclear whether Peter White already knew these results at the time of his Swiss Re presentation on the PACE results.

Update 11/18/15 6:54 AM: I also forgot to mention in the story that the three principal PACE investigators did not respond to an e-mail seeking comment about their insurance industry work. Lancet editor Richard Horton also did not respond to an e-mail seeking comment.





6 responses to “PACE Team’s Work for Insurance Companies Is “Not Related” to PACE. Really? (Reprise)”

  1. Sue Klaus Avatar
    Sue Klaus

    The Swiss re link above now opens up to a 404 page:
    “404 ERROR
    Page not found

    Oops! Looks like you got lost in space.”

    The last thing I look for in a disability insurance company, is whimsy.

    If only we could subpoena the financial records for Wesley and Sharp and everyone else associated with the Pace trial I’m sure it would be illuminating.

  2. Thane Avatar

    Incidentally, all that seems necessary to trash Michael Sharpe’s work is to shine a light on it, and…. wha la….. trash.

  3. SusanC Avatar

    I think I’d trash Sharpe’s work for free too (e.g. as a referee for one of these junk CBT papers)

    Though the main reason I’m reading your blog is that I’m hoping I don’t make any of the same methodological mistakes in the stuff that I am being paid to write.

  4. SusanC Avatar

    Some source of research funding will demand that they get to censor all publications arising from the research they funded. (It my experience, it can depend on the specific contract, not just which government funding body). This is potentially problematic, as it can lead to the researcher having to “spin” findings that the source of the money doesn’t like.

    I do wonder if this is what happened here. It would explain a lot.

    A suggestion for any lawyers reading this who ever get involved in litigation over research: the draft version of the paper *before* the source of the money demanded changes might be obtainable via discovery in litigation, and might usefully be compared with what was actually published…

  5. jimells Avatar

    Initial tobacco industry litigation failed, but advocates kept at it. When state attorneys general got a whiff of blood in the water, they all piled on, litigation succeeded, and state coffers received large payouts.

    Similar has happened to the opiate drug industry. Once again attorneys general saw an opportunity to extract cash from corporate coffers so they coughed up the resources needed to win the litigation.

    State budget officers are desperate for cash and will soon learn that the needs of Long Covid patients will break their budgets. Insurance industry cash will be a tempting treat, especially when attorneys general learn that there is a criminal conspiracy to bury an illness. The result is there are no effective treatments for post viral illness while patients are abused and driven to end their own lives.

    The Nixon era taught us that the coverup is worse than the crime. In this case the PACE people are covering up immense harm done to trial participants. That is why they spent a quarter-million pounds on lawyers to keep the data hidden.

    Sharpe is constantly bleating that he is silenced, that he needs a bigger podium. So let’s give him a very big and public podium in the form of a courthouse witness box. I guarantee he will have a large and very attentive audience.

  6. MK Avatar

    Insurance companies could not care less whether the patient actually returns to work. What insurance companies care about is whether the patient’s illness is categorized as one that does not qualify for costly medical treatment or disability. This is applicable to ANY patient who has an illness that is not effectively treated or diagnosed but is severely disabling. By only treating or offering disability to those who are diagnosed with the RIGHT disease many people who are almost 100% disabled can be left untreated and without disability assistance. It can take some patients 10 years to get a diagnosis. What should they eat in the meantime? Air?